In vivo, genetic deletion of BAX and BAK, or MAVS, in a mouse model of metabolic dysfunction–associated steatohepatitis (MASH) led to a reduction of the SASP and improved functional parameters in livers. The gene discussed is BAK1; the disease is metabolic dysfunction-associated steatohepatitis.